Protagonist Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

TrialDrugs studiedStatusPrimary completion
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraNCT06033586Open-label rusfertideActive not recruiting2026-04-01Estimated
A Study of Rusfertide in Adults With Polycythemia Vera (PV)NCT05210790RusfertideActive not recruiting2025-02-21Actual

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790 · Protagonist Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving a response who receive rusfertide compared to placebo. Description: Response is defined as absence of phlebotomy eligibility. Time frame: Week 20 through Week 32. After: Measure: Part 1a: Percentage of Participants Who Achieved Response Description: Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%. Time frame: From Weeks 20 to 32.

Check registry source